Compare DLPN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | SNTI |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 24.5M |
| IPO Year | 2008 | 2021 |
| Metric | DLPN | SNTI |
|---|---|---|
| Price | $1.61 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 11.9K | ★ 100.3K |
| Earning Date | 03-25-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,684,984.00 | N/A |
| Revenue This Year | $10.62 | N/A |
| Revenue Next Year | $13.78 | $150.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $0.75 | $0.80 |
| 52 Week High | $1.88 | $5.10 |
| Indicator | DLPN | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 43.49 |
| Support Level | $1.51 | $0.80 |
| Resistance Level | $1.71 | $1.02 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 44.90 | 23.71 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.